Immix Biopharma, Inc. (IMMX) Stock Price & Analysis
Immix Biopharma, Inc. (IMMX) fell 3.81% to USD 13.38 as of September 8, 2026 at 16:14 UTC, according to Nexqual real-time market data.
IMMX last closed at USD 13.38; the session ranged USD 12.75–13.89 on volume of 488,603 shares. Market capitalization is —, with a 52-week range of USD 1.94–15.1 (NCM). Source: Nexqual, September 8, 2026 at 16:14 UTC.
Key Statistics (as of September 8, 2026 at 16:14 UTC)
| Price | USD 13.38 |
|---|---|
| Change | ▼ 3.81% (down) |
| Previous Close | USD 13.38 |
| Open | USD 13.38 |
| Day Range | USD 12.75 – 13.89 |
| 52-Week Range | USD 1.94 – 15.1 |
| Volume | 488,603 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (IMMX)
Nexqual's technical model rates IMMX "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of September 8, 2026 at 16:14 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.11 (neutral) |
| vs SMA50 | Above (USD 11.09) |
| MACD | 0.95 (positive) |
From Immix Biopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Any resulting patents in this family are expected to expire in 2043 (not including any patent term adjustment and patent term extension in the United States and equivalents in foreign countries).     We also have global exclusive rights to PCT Application No.
- We believe that we have substantial know-how and trade secrets relating to our technology and product candidates.     As of March 2026, we have global exclusive rights to PCT Application No.
- The global amyloidosis treatment market size was estimated at $5.80 billion in 2024 and is projected to reach $11.13 billion by 2033, growing at a CAGR of 7.5% from 2025 to 2033, according to Grand View Research.   As of March 2026, there are no FDA approved drugs for relapsed/refractory AL Amyloidosis.   Figure 2: NXC-201 Addresses Sizable U.S.
- CAR-T cell therapy is a type of immunotherapy that uses the patient's own immune cells, modified with our proprietary technology, to create NXC-201, which is then introduced into the patient's body.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BFRI | Biofrontera Inc. | USD 1.57 | ▲ 3.64% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.6 | ▲ 2.93% |
| NRSN | NeuroSense Therapeutics Ltd. | USD 0.41 | ▲ 2.91% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.46 | ▲ 4.3% |
| PTPI | Petros Pharmaceuticals, Inc. | USD 0.01 | ▲ 60% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 16:14 UTC. This page is informational and not investment advice.